Inherit For Three Thousand Years

Just as the outside world reported on this contemporary artist's art exhibition in full swing, a series of sniping methods against Tiansheng Pharmaceutical had quietly begun.

First, the "Hong Kong Island Daily" published a headline on the front page, publicly questioning Tiansheng Pharmaceutical's financial fraud.

Then a number of media followed up the news. Under the overwhelming negative publicity, Tiansheng Pharmaceutical's stock price fell sharply.

In just three days, Tiansheng Pharmaceutical, which had a market value of 102.5 billion at its peak, actually lost nearly 10 billion in market value, and its market value could barely keep 90 billion.

Tiansheng Pharmaceutical launched an emergency research, angrily denouncing the "Hong Kong Island Daily" and other unscrupulous media for deliberately exaggerating the facts, which caused huge losses to the company. The legal responsibility of these unscrupulous media.

Qin Huali himself is the big sponsor behind the "Hong Kong Island Daily". He completely ignored Tiansheng Pharmaceutical's warning and continued to release various negative news about Tiansheng Pharmaceutical.

Within a week, the market value of Tiansheng Pharmaceutical continued to shrink, from 100 billion to 86 billion.

Tiansheng Pharmaceutical did everything possible to refute the rumors, and finally stopped the decline of the stock price. The second wave of attacks against Tiansheng Pharmaceutical came soon.

Still, "Hong Kong Island Daily" was the first to disclose the news that the new drug for the treatment of cardiovascular and cerebrovascular diseases that Tiansheng Pharmaceutical spent huge sums of money on research had serious side effects, and finally announced the failure of the research.

The content of this report is very detailed, and all the details of the research process have been disclosed.

The final failure of this drug directly led to a huge research investment of 5 billion accumulated over the years, which was in vain.

The outside world is very optimistic and supportive of Tiansheng Pharmaceutical's huge investment in the research and development of original research drugs. Moreover, in the past few years, the research and development of this original research drug has been very smooth, and good news will be disclosed from time to time, which has played a positive role in promoting the stock price.

Everyone knows that investment in original research medicine is a bottomless pit, and it is not so easy to obtain research results. Success is gratifying, but failure is also normal.

But the mistake of Tiansheng Pharmaceutical is that it is too high-profile about R\u0026D, and it has repeatedly used this method to raise investors' expectations, thereby pushing up the stock price. This has led to the fact that the majority of shareholders can only accept success, but cannot accept the cruel reality of R\u0026D failure.

Now that the final research has failed, the blow to confidence is huge.

As much as Tiansheng Pharmaceutical's stock price has increased with the help of new drug research and development, it will fall as much as it is now. Even under the deliberate promotion of the sniper team, the decline was greater and faster.

On the day the news was disclosed, Tiansheng Pharmaceutical's stock price plummeted again.

The negative news this time is real. All kinds of real hammers are constantly disclosed. Tiansheng Pharmaceutical's dry explanation and explanation of continuing to increase investment in original research drugs are of no help at all.

After the stock price of Tiansheng Pharmaceutical fell sharply, it continued to decline. In just 5 days, the original market value of 100 billion shrank to 65 billion.

The management of Tiansheng Pharmaceutical has been exhausted during this period of time. They have tried everything possible, but they still can't stop the sinister situation where the stock price continues to fall.

Just when the majority of stockholders thought that Tiansheng Pharmaceutical's stock price had bottomed out and was about to rebound, the real fatal blow came suddenly.

Yuanhang Pharmaceutical Co., Ltd. and kpg Drug Research Institute jointly held a press conference, and invited journalists from major media to attend in a high-profile manner.

Yuanhang Pharmaceutical is little-known, it is just a medium-sized pharmaceutical company in Nanyang, but the kpg Drug Research Institute is well-known, and has launched a number of best-selling drugs in a row in the past few years. The media still takes it seriously.

With such a high-profile press conference, the content is really explosive.

Two best-selling new drugs for the treatment of cardiovascular and cerebrovascular diseases from the Kpg Institute of Drug Research, the exclusive patent authorization for the next 15 years was actually won by Yuanhang Pharmaceutical in one fell swoop.

If the news is limited to this, it is not sensational enough, but if the authorized patents of these two drugs were snatched from Tiansheng Pharmaceutical,

The impact of this news is great.

The "Hong Kong Island Daily" responded the fastest. Just after the press conference ended, a detailed analysis of this piece of information was published on the official website.

Only through the disclosure of "Hong Kong Island Daily" did the stockholders know that Tiansheng Pharmaceutical's sales performance has increased year by year in the past few years, and the main contributors are these two new drugs of KPG.

The profit of these two new drugs actually accounted for nearly half of the annual profit. Originally, this was good news to increase the stock price, but now that Tiansheng Pharmaceutical has not won the follow-up patent license, the good news has suddenly become a reminder.

Losing the patent licenses of these two drugs means that Tiansheng Pharmaceutical will lose nearly half of its profits every year, which is simply unbearable.

This blow is fatal!

The disclosure of this news is tantamount to digging out the main root of the big tree of Tiansheng Medicine. If there is a little carelessness, Tiansheng Medicine is in danger of collapsing.

Fall...fall...still fall!

The stock price of Tiansheng Pharmaceutical began to fall precipitously, and within three days, it fell below the issue price.

A week later, Tiansheng Pharmaceutical's market value shrank to 45 billion.

So far, the stock price has bottomed out, and there is basically no room for shrinkage.

Tiansheng Pharmaceutical is not an asset-light Internet stock. The market value of 45 billion is already underestimated, and it is impossible to continue to fall.

The tradable shares of Tiansheng Pharmaceutical accounted for 40% of the total share capital. Qin Huali's acquisition team, together with Swire Investment, acquired a total of 30% of the shares from the market, and the acquisition funds were only 16 billion yuan.

The matter came too suddenly, Zeng Zhaoquan was very vigilant about the sudden appearance of the two major shareholders, and wanted to increase his shareholding, but it was a pity that he could not come up with funds for a while.

After he mortgaged his shares and successfully got the loan, there were not many tradable shares in the market. Zeng Zhaoquan only increased his own shares from 35% to 40%.

The negotiations with these seven shareholders fully demonstrated Qin Huali's strong energy. He invested a total of 13 billion yuan at an average premium of 15%, and successfully won the 25% of the shares.

So far, Qin Huali has won 55% of the shares, and the total acquisition funds invested are 29 billion yuan.